Abstract
The endocannabinoid system comprises amides, esters and ethers of long chain polyunsaturated fatty acids. Narachidonoylethanolamide (anandamide; ANA) and 2-arachidonoylglycerol (2-AG) are endogenous cannabinoids (endocannabinoids) ligands for the cannabinoid family of G-protein-coupled receptors named CB1 and CB2. Endocannabinoids are released upon demand from lipid precursors in a receptor-dependent manner and behave as retrograde signaling messengers, as well as modulators of postsynaptic transmission, interacting with other neurotransmitters systems. The two principal enzymes that are responsible for the metabolism of ANA and 2-AG are fatty acid amide hydrolase and monoacylglycerol lipase, respectively. Pharmacological experiments have shown that the administration of endocannabinoids induce cannabimimetic effects, including sleep promotion. This review will focus on some of the current evidence of the pharmacological potential of the endocannabinoid system on sleep modulation.
Keywords: Anandamide, cannabinoids, cannabidiol, rapid eye movement sleep, cannabinoid receptors, VDM-11
Central Nervous System Agents in Medicinal Chemistry
Title: The Emerging Role of the Endocannabinoid System in the Sleep-Wake Cycle Modulation
Volume: 11 Issue: 3
Author(s): Eric Murillo-Rodriguez, Alwin Poot-Ake, Oscar Arias-Carrion, Elda Pacheco-Pantoja, Alfredo de la Fuente-Ortegon and Gloria Arankowsky-Sandoval
Affiliation:
Keywords: Anandamide, cannabinoids, cannabidiol, rapid eye movement sleep, cannabinoid receptors, VDM-11
Abstract: The endocannabinoid system comprises amides, esters and ethers of long chain polyunsaturated fatty acids. Narachidonoylethanolamide (anandamide; ANA) and 2-arachidonoylglycerol (2-AG) are endogenous cannabinoids (endocannabinoids) ligands for the cannabinoid family of G-protein-coupled receptors named CB1 and CB2. Endocannabinoids are released upon demand from lipid precursors in a receptor-dependent manner and behave as retrograde signaling messengers, as well as modulators of postsynaptic transmission, interacting with other neurotransmitters systems. The two principal enzymes that are responsible for the metabolism of ANA and 2-AG are fatty acid amide hydrolase and monoacylglycerol lipase, respectively. Pharmacological experiments have shown that the administration of endocannabinoids induce cannabimimetic effects, including sleep promotion. This review will focus on some of the current evidence of the pharmacological potential of the endocannabinoid system on sleep modulation.
Export Options
About this article
Cite this article as:
Murillo-Rodriguez Eric, Poot-Ake Alwin, Arias-Carrion Oscar, Pacheco-Pantoja Elda, de la Fuente-Ortegon Alfredo and Arankowsky-Sandoval Gloria, The Emerging Role of the Endocannabinoid System in the Sleep-Wake Cycle Modulation, Central Nervous System Agents in Medicinal Chemistry 2011; 11 (3) . https://dx.doi.org/10.2174/187152411798047780
DOI https://dx.doi.org/10.2174/187152411798047780 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Choline Nutrition Programs Brain Development Via DNA and Histone Methylation
Central Nervous System Agents in Medicinal Chemistry Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry Mechanisms of Microcystin-induced Cytotoxicity and Apoptosis
Mini-Reviews in Medicinal Chemistry Employing New Cellular Therapeutic Targets for Alzheimers Disease: A Change for the Better?
Current Neurovascular Research Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Conformational Changes of Prion Protein and Nucleic Acid Arising from their Interaction and Relation of the Altered Structures in Causing Prion Disease
Mini-Reviews in Medicinal Chemistry Central Nervous System Agents Used as Trypanosoma cruzi Infection Chemotherapy: Phenothiazines and Related Compounds
Current Medicinal Chemistry - Anti-Infective Agents Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective
Current Alzheimer Research Interactions of VDAC with Proteins Involved in Neurodegenerative Aggregation: An Opportunity for Advancement on Therapeutic Molecules
Current Medicinal Chemistry Early Chronic Stress Induced Changes within the Locus Coeruleus in Sporadic Alzheimer’s Disease
Current Alzheimer Research Biological Role of Formaldehyde, and Cycles Related to Methylation, Demethylation, and Formaldehyde Production
Mini-Reviews in Medicinal Chemistry Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology
Current Pharmaceutical Design Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer
Current Signal Transduction Therapy Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics
Current Pharmaceutical Design Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers Inhibition of Protein Misfolding and Aggregation by Small Rationally-Designed Peptides
Current Pharmaceutical Design Recent Developments of Flavonoids with Various Activities
Current Topics in Medicinal Chemistry